尼古丁胺胺基基转移酶 (NAMPT) 作为宫前入侵性病变的新标记物
Eda Kayali1, Gunsu Kimyon Comert1, Hülya Tosun Yildirim2
1Department of Gynecological Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.
International journal of surgical pathology
|September 29, 2025
概括
尼古丁胺胺酸基转移酶 (NAMPT) 水平在高度宫发育不良 (CIN 2-3) 中显著升高. 这一发现表明,NAMPT可能成为诊断子宫前恶性病变的有价值生物标志物.
科学领域:
- 妇科瘤学 妇科瘤学
- 分子病理学分子病理学
- 生物标志物发现发现
背景情况:
- 宫发育不良症是一种先发性疾病,需要准确的诊断标志物.
- 人类乳头瘤病毒 (HPV) 阳性是宫发育不良的主要危险因素.
- 尼古丁胺胺酸基转移酶 (NAMPT) 是一种参与NAD+生物合成的酶,在细胞增殖和癌症中具有潜在的作用.
研究的目的:
- 调查宫发育不良症严重程度与NAMPT组织表达水平之间的关联.
- 评估NAMPT作为诊断标记物的潜力,以区分正常的宫组织,低度 (CIN 1) 和高度 (CIN 2-3) 的宫内皮质瘤.
主要方法:
- 分析了86名接受结肠镜活检的患者的组织样本,以检测HPV阳性.
- 样品被分类为正常,CIN 1或CIN 2-3,并对NAMPT表达进行染色.
- 评分了NAMPT染色强度和百分比阳性,并为每个标本计算了产品评分.
主要成果:
- 与CIN1/正常病例相比,在CIN2-3病例中观察到显著更高的NAMPT染色得分 (90%与9%,P<.000).
- 在CIN 1和正常组织中没有强烈的NAMPT染色.
- 产品分数截止值为2显示了检测CIN2-3的高灵敏度 (96%) 和负预测值 (98%).
结论:
- 在不同级别的宫发育不良症中,NAMPT组织水平显著不同.
- NAMPT表达可以作为一个有前途的生物标志物来区分CIN 2-3与正常或CIN 1的宫组织.
- 这种生物标志物有可能提高宫前恶性病变的诊断准确度.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...


